BRPI0817973A2 - derivados de nicotinamida, o respectivo preparo e a respectiva aplicação em terapêutica - Google Patents

derivados de nicotinamida, o respectivo preparo e a respectiva aplicação em terapêutica

Info

Publication number
BRPI0817973A2
BRPI0817973A2 BRPI0817973-5A BRPI0817973A BRPI0817973A2 BR PI0817973 A2 BRPI0817973 A2 BR PI0817973A2 BR PI0817973 A BRPI0817973 A BR PI0817973A BR PI0817973 A2 BRPI0817973 A2 BR PI0817973A2
Authority
BR
Brazil
Prior art keywords
group
preparation
hydrogen atom
therapeutic
nicotinamide derivatives
Prior art date
Application number
BRPI0817973-5A
Other languages
English (en)
Inventor
Arigon Jerôme
Bernhart Claude
Bouaboula Monsif
Casellas Pierre
Combet Romain
Jegham Samir
Hilairet Sandrine
Fraisse Pierre
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of BRPI0817973A2 publication Critical patent/BRPI0817973A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de nicotinamida, sua preparação e sua aplicação em terapêutica a presente invenção refere-se a um composto de fórmula (1): em que: . a representa um grupo -nr1 r'1 ou (c1-c6)alcóxi; z e z' representam respectivamente n e ch; n e cf; n e n; ch e ch; ch e n; l representa um grupo -ch=ch- ou -chzchz- ou -(chz)n-y-,. r1 e r'1 são tais que: (i) r1 representa: - um átomo de hidrogênio; - um grupo arila eventualmente substituído por um ou vários átomos de halogênio; - um grupo heteroarila; - um grupo (c3-cs)cicloalquila; -um grupo (c1-cs) alquila, e r'1 representa um átomo de hidrogênio ou um grupo (c1-c6) alquila; ou (11) r1 e r'1 forma juntos com o átomo de nitrogênio ao qual são ligados um grupo heterocicloalquila; rz representa um grupo -q-~; q representa um átomo de oxigênio ou o grupo -nh-; ~ representa: - um átomo de hidrogênio; - um grupo heteroarila; - um grupo (c3-cs) cicloalquila; - um grupo (c1-c6) alquila, eventualmente substituído; r3 representa pelo menos um substituinte do núcleo piridina
BRPI0817973-5A 2007-09-28 2008-09-26 derivados de nicotinamida, o respectivo preparo e a respectiva aplicação em terapêutica BRPI0817973A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0706799 2007-09-28
FR0706799A FR2921657A1 (fr) 2007-09-28 2007-09-28 Derives de nicotinamide, leur preparation et leur application en therapeutique
PCT/FR2008/001338 WO2009074749A2 (fr) 2007-09-28 2008-09-26 Dérives de nicotinamide. leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
BRPI0817973A2 true BRPI0817973A2 (pt) 2019-04-09

Family

ID=39356668

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817973-5A BRPI0817973A2 (pt) 2007-09-28 2008-09-26 derivados de nicotinamida, o respectivo preparo e a respectiva aplicação em terapêutica

Country Status (19)

Country Link
US (1) US20100222319A1 (pt)
EP (1) EP2205566A2 (pt)
JP (1) JP2010540504A (pt)
KR (1) KR20100065165A (pt)
CN (1) CN101808996A (pt)
AR (1) AR066171A1 (pt)
AU (1) AU2008334457A1 (pt)
BR (1) BRPI0817973A2 (pt)
CA (1) CA2700559A1 (pt)
CL (1) CL2008002893A1 (pt)
FR (1) FR2921657A1 (pt)
IL (1) IL204663A0 (pt)
MX (1) MX2010003445A (pt)
PA (1) PA8797301A1 (pt)
PE (1) PE20091033A1 (pt)
RU (1) RU2010116765A (pt)
TW (1) TW200918056A (pt)
UY (1) UY31367A1 (pt)
WO (1) WO2009074749A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
MX365732B (es) 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
FR2943675A1 (fr) * 2009-03-24 2010-10-01 Sanofi Aventis Composes anticancereux, leur preparation et leur application en therapeutique
FR2943670B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives anticancereux,leur preparation et leur application en therapeutique
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
EP2440204B1 (en) * 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
AU2011223790A1 (en) * 2010-03-01 2012-08-30 Myrexis, Inc. Compounds and therapeutic uses thereof
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
US8827372B2 (en) 2010-07-07 2014-09-09 Frontis Corp. Blowing system
FR2965263A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
CN103012397B (zh) * 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
PT2573073E (pt) * 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN103804270B (zh) * 2014-01-23 2016-06-22 中国药科大学 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
JP7092356B2 (ja) * 2016-06-22 2022-06-28 フーダン ユニヴァーシティ ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
KR102831570B1 (ko) 2018-05-04 2025-07-10 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
CN110396065A (zh) * 2019-06-25 2019-11-01 南京普锐达医药科技有限公司 一种2,4-二氯-5-嘧啶甲酰氯的合成方法
AU2020378067A1 (en) * 2019-11-06 2022-05-26 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2021219513A1 (en) 2020-04-28 2021-11-04 Basf Se Pesticidal compounds
JP2024518089A (ja) * 2021-05-13 2024-04-24 リメディー プラン，インコーポレーテッド Ｎａｍｐｔ阻害剤とその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4301110A1 (de) * 1993-01-18 1994-07-21 Bayer Ag Verfahren zur Herstellung von 2-Amino-5-aminomethyl-pyridin
CZ20012185A3 (cs) * 1998-12-16 2001-10-17 Bayer Aktiengesellschaft Nové bifenylové sloučeniny a sloučeniny analogické bifenylovým sloučeninám, způsob jejich přípravy, farmaceutické prostředky a pouľití těchto sloučenin a prostředků jako antagonistů integrinu
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
JP2007515400A (ja) * 2003-11-28 2007-06-14 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer

Also Published As

Publication number Publication date
AU2008334457A1 (en) 2009-06-18
WO2009074749A2 (fr) 2009-06-18
WO2009074749A3 (fr) 2009-08-20
CN101808996A (zh) 2010-08-18
RU2010116765A (ru) 2011-11-27
PA8797301A1 (es) 2009-05-15
FR2921657A1 (fr) 2009-04-03
MX2010003445A (es) 2010-04-27
CA2700559A1 (fr) 2009-06-18
EP2205566A2 (fr) 2010-07-14
PE20091033A1 (es) 2009-08-17
US20100222319A1 (en) 2010-09-02
UY31367A1 (es) 2009-04-30
CL2008002893A1 (es) 2009-10-16
KR20100065165A (ko) 2010-06-15
IL204663A0 (en) 2010-11-30
AR066171A1 (es) 2009-07-29
JP2010540504A (ja) 2010-12-24
TW200918056A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
BRPI0817973A2 (pt) derivados de nicotinamida, o respectivo preparo e a respectiva aplicação em terapêutica
MX2009011532A (es) Derivados de piridina sustituidos por un anillo heterociclico y grupo fosfonoamino, y agente anti-fungal que contiene los mismos.
UA97836C2 (ru) Производные плевромутилина для лечения заболеваний, вызванных микробами
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
DK1414302T3 (da) 7-aminotriazolopyrimidiner til bekæmpelse af skadelige svampe
EA201071111A1 (ru) ПОЛИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 6-ГЕТЕРОАРИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
MY153393A (en) Amino nicotinic and isonicotinic acid derivatives as dhodh as inhibitors
IN2012DN00573A (pt)
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
NZ596615A (en) Substituted isoquinoline derivative
MX2009011212A (es) Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
MX2009012380A (es) Compuestos de heteroarilamida pirimidona.
WO2009118473A3 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
MY168283A (en) Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
WO2008136444A1 (ja) 縮合複素環誘導体
EA200971063A1 (ru) Ариламидпиримидоновые соединения
DK1601653T3 (da) Fremgangsmåde til fremstilling af substituerede nikotinsyreestre
BRPI0606845A2 (pt) derivados de (1,5-difenil-1h-pirazol-3-il)oxadiazol, o respectivo preparo e a respectiva aplicação em terapêutica
EA201070010A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.
NO20072454L (no) Pyridinderivater, fremstillingen og den terapeutiske anvendelse derav

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]